# Master Documentation Index
## Ternary VAE Bioinformatics - 8 Easy Research Implementations

**Date:** December 29, 2025
**Status:** COMPLETE - All Deliverables Ready

---

## Overview

This document provides a complete index of all 8 "Easy" research implementations delivered to our partners. Each tool has been tested in demo mode and includes comprehensive documentation.

---

## Quick Navigation

| Tool ID | Name | Partner | Status |
|---------|------|---------|--------|
| [A2](#a2-pan-arbovirus-primer-library) | Pan-Arbovirus Primer Library | Alejandra Rojas | Complete |
| [B1](#b1-pathogen-specific-amp-design) | Pathogen-Specific AMP Design | Carlos Brizuela | Complete |
| [B8](#b8-microbiome-safe-amps) | Microbiome-Safe AMPs | Carlos Brizuela | Complete |
| [B10](#b10-synthesis-optimization) | Synthesis Optimization | Carlos Brizuela | Complete |
| [C1](#c1-rosetta-blind-detection) | Rosetta-Blind Detection | Jose Colbes | Complete |
| [C4](#c4-mutation-effect-predictor) | Mutation Effect Predictor | Jose Colbes | Complete |
| [H6](#h6-tdr-screening) | TDR Screening | HIV Package | Complete |
| [H7](#h7-la-injectable-selection) | LA Injectable Selection | HIV Package | Complete |

---

## A2: Pan-Arbovirus Primer Library

**Partner:** Alejandra Rojas (IICS-UNA)
**Application:** Arbovirus molecular diagnostics

### Purpose
Design RT-PCR primers for differential diagnosis of 7 arboviruses circulating in Paraguay and Latin America.

### Target Viruses
- Dengue (DENV-1, 2, 3, 4)
- Zika (ZIKV)
- Chikungunya (CHIKV)
- Mayaro (MAYV)

### Key Files
| File | Description |
|------|-------------|
| `scripts/A2_pan_arbovirus_primers.py` | Main implementation |
| `docs/A2_USER_GUIDE.md` | User guide |
| `docs/A2_TECHNICAL_DOCS.md` | Technical documentation |
| `results/pan_arbovirus_primers/` | Demo output |

### Quick Start
```bash
python deliverables/scripts/A2_pan_arbovirus_primers.py
```

### Demo Results
- 70 primer candidates across 7 viruses
- GC content: 40-60%
- Tm range: 55-65C

---

## B1: Pathogen-Specific AMP Design

**Partner:** Carlos Brizuela
**Application:** Antimicrobial peptide discovery

### Purpose
Design antimicrobial peptides targeting specific WHO priority pathogens using NSGA-II optimization.

### Target Pathogens
- *Acinetobacter baumannii* (Critical)
- *Pseudomonas aeruginosa* (Critical)
- *Klebsiella pneumoniae* (Critical)
- *Staphylococcus aureus* (High)

### Key Files
| File | Description |
|------|-------------|
| `scripts/B1_pathogen_specific_design.py` | Main implementation |
| `docs/B1_USER_GUIDE.md` | User guide |
| `results/pathogen_specific/` | Demo output |

### Quick Start
```bash
python deliverables/scripts/B1_pathogen_specific_design.py
```

### Demo Results
- 15 Pareto-optimal candidates
- Net charge: +2 to +6.5
- Zero predicted toxicity

---

## B8: Microbiome-Safe AMPs

**Partner:** Carlos Brizuela
**Application:** Selective antimicrobial therapy

### Purpose
Design peptides that kill pathogens while sparing beneficial commensal bacteria.

### Key Metric: Selectivity Index
```
SI = Commensal MICs / Pathogen MICs
SI > 1 = Selective for pathogens
```

### Key Files
| File | Description |
|------|-------------|
| `scripts/B8_microbiome_safe_amps.py` | Main implementation |
| `docs/B8_USER_GUIDE.md` | User guide |
| `results/microbiome_safe/` | Demo output |

### Quick Start
```bash
python deliverables/scripts/B8_microbiome_safe_amps.py
```

### Demo Results
- 20 candidates with SI > 1.0
- Best sequence: HNHWHMNWKKKKAYAHKPGR
- Net charge: +8

---

## B10: Synthesis Optimization

**Partner:** Carlos Brizuela
**Application:** Practical peptide manufacturing

### Purpose
Balance antimicrobial activity with synthesis feasibility (cost, difficulty, yield).

### Metrics Optimized
- Aggregation propensity
- Racemization risk
- Coupling efficiency
- Estimated cost

### Key Files
| File | Description |
|------|-------------|
| `scripts/B10_synthesis_optimization.py` | Main implementation |
| `docs/B10_USER_GUIDE.md` | User guide |
| `results/synthesis_optimized/` | Demo output |

### Quick Start
```bash
python deliverables/scripts/B10_synthesis_optimization.py
```

### Demo Results
- Activity: 0.88-0.93
- Synthesis difficulty: 14-16
- Coupling efficiency: 47-52%

---

## C1: Rosetta-Blind Detection

**Partner:** Jose Colbes
**Application:** Protein stability analysis

### Purpose
Identify residues where Rosetta underestimates instability, using p-adic geometric scoring.

### Key Finding
**23.6% of residues are "Rosetta-blind"** - geometrically unstable but Rosetta-stable.

### Key Files
| File | Description |
|------|-------------|
| `scripts/C1_rosetta_blind_detection.py` | Main implementation |
| `docs/C1_USER_GUIDE.md` | User guide |
| `results/rosetta_blind/` | Demo output |

### Quick Start
```bash
python deliverables/scripts/C1_rosetta_blind_detection.py
```

### Demo Results
- 500 residues analyzed
- 118 Rosetta-blind (23.6%)
- Most affected: LEU, ARG, TRP, MET, VAL

---

## C4: Mutation Effect Predictor

**Partner:** Jose Colbes
**Application:** Protein engineering

### Purpose
Predict stability change (DDG) for point mutations using p-adic features.

### Classification
| DDG Range | Classification |
|-----------|----------------|
| < -1.0 | Stabilizing |
| -1.0 to +1.0 | Neutral |
| > +1.0 | Destabilizing |

### Key Files
| File | Description |
|------|-------------|
| `scripts/C4_mutation_effect_predictor.py` | Main implementation |
| `docs/C4_USER_GUIDE.md` | User guide |
| `results/mutation_effects/` | Demo output |

### Quick Start
```bash
python deliverables/scripts/C4_mutation_effect_predictor.py
```

### Demo Results
- 21 mutations analyzed
- 7 destabilizing (33%)
- 13 neutral (62%)
- 1 stabilizing (5%)

---

## H6: TDR Screening

**Partner:** HIV Research Package
**Application:** HIV clinical decision support

### Purpose
Screen treatment-naive patients for transmitted drug resistance mutations.

### Mutations Screened
- NRTI: M184V, K65R, TAMs
- NNRTI: K103N, Y181C, G190A
- INSTI: Q148H/R/K, N155H

### Key Files
| File | Description |
|------|-------------|
| `scripts/H6_tdr_screening.py` | Main implementation |
| `docs/H6_USER_GUIDE.md` | User guide |
| `results/tdr_screening/` | Demo output |

### Quick Start
```bash
python deliverables/scripts/H6_tdr_screening.py
```

### Demo Results
- 5 patients screened
- 0% TDR positive (demo mode)
- All susceptible to 12 first-line drugs

---

## H7: LA Injectable Selection

**Partner:** HIV Research Package
**Application:** HIV treatment optimization

### Purpose
Assess patient eligibility for long-acting cabotegravir/rilpivirine (CAB/RPV-LA) therapy.

### Eligibility Criteria
- Viral suppression (VL < 50)
- No CAB/RPV resistance
- PK adequacy (BMI, injection site)
- Adherence history

### Key Files
| File | Description |
|------|-------------|
| `scripts/H7_la_injectable_selection.py` | Main implementation |
| `docs/H7_USER_GUIDE.md` | User guide |
| `results/la_selection/` | Demo output |

### Quick Start
```bash
python deliverables/scripts/H7_la_injectable_selection.py
```

### Demo Results
- 5 patients assessed
- 2 eligible (40%)
- Mean success probability: 83.5%

---

## Directory Structure

```
deliverables/
├── alejandra_rojas/
│   ├── README.md                 # Package overview
│   ├── scripts/                  # A2 + existing scripts
│   ├── docs/
│   │   ├── A2_USER_GUIDE.md
│   │   └── A2_TECHNICAL_DOCS.md
│   └── results/
│
├── carlos_brizuela/
│   ├── README.md                 # Package overview
│   ├── scripts/                  # B1, B8, B10 + existing
│   ├── docs/
│   │   ├── B1_USER_GUIDE.md
│   │   ├── B8_USER_GUIDE.md
│   │   └── B10_USER_GUIDE.md
│   └── results/
│
├── jose_colbes/
│   ├── README.md                 # Package overview
│   ├── scripts/                  # C1, C4 + existing
│   ├── docs/
│   │   ├── C1_USER_GUIDE.md
│   │   └── C4_USER_GUIDE.md
│   └── results/
│
├── hiv_research_package/
│   ├── README.md                 # Package overview
│   ├── scripts/                  # H6, H7 + existing
│   ├── docs/
│   │   ├── H6_USER_GUIDE.md
│   │   └── H7_USER_GUIDE.md
│   └── results/
│
├── scripts/
│   └── vae_integration_demo.py   # VAE connection demo
│
├── DEMO_RESULTS_ANALYSIS.md      # Comprehensive results analysis
└── MASTER_DOCUMENTATION_INDEX.md # This file
```

---

## VAE Integration

All tools can connect to the Ternary VAE for enhanced functionality:

```python
from deliverables.scripts.vae_integration_demo import VAEInterface

# Initialize with checkpoint
vae = VAEInterface(checkpoint_path="checkpoints/pretrained_final.pt")

# Decode latent vector to sequence
sequence = vae.decode_latent(z)

# Encode sequence to latent space
z = vae.encode_sequence("KLWKKLKKALK")

# Get stability metrics
radius = vae.get_radius(z)
valuation = vae.get_padic_valuation(z)
```

---

## Running All Demos

```bash
# From project root
cd deliverables/scripts

# A2: Arbovirus Primers
python A2_pan_arbovirus_primers.py

# B1, B8, B10: AMP Design
python B1_pathogen_specific_design.py
python B8_microbiome_safe_amps.py
python B10_synthesis_optimization.py

# C1, C4: Protein Stability
python C1_rosetta_blind_detection.py
python C4_mutation_effect_predictor.py

# H6, H7: HIV Clinical
python H6_tdr_screening.py
python H7_la_injectable_selection.py

# VAE Integration
python vae_integration_demo.py
```

---

## Summary Table

| Tool | Partner | Domain | Key Output |
|------|---------|--------|------------|
| A2 | Rojas | Virology | 70 primers, 7 viruses |
| B1 | Brizuela | Antibiotics | 15 pathogen-specific AMPs |
| B8 | Brizuela | Microbiome | 20 selective AMPs |
| B10 | Brizuela | Manufacturing | Synthesis-optimized peptides |
| C1 | Colbes | Proteins | 23.6% Rosetta-blind residues |
| C4 | Colbes | Engineering | DDG predictions |
| H6 | HIV | Clinical | TDR screening |
| H7 | HIV | Clinical | LA eligibility |

---

## Next Steps

### For Production Use
1. Connect to real VAE checkpoint
2. Train pathogen-specific activity predictors
3. Integrate Stanford HIVdb for resistance
4. Deploy clinical tools in pilot settings

### For Validation
1. Test with real NCBI arbovirus sequences
2. Compare AMP predictions with experimental MICs
3. Validate DDG predictions against ProTherm
4. Clinical validation of H6/H7 against outcomes

---

*Part of the Ternary VAE Bioinformatics Partnership*
*December 2025*
